Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navoximod and NLG802 with SBRT in Advanced Solid Tumors
NCT05469490Phase 1Withdrawn
- Start
- Oct 2022
- Primary completion
- Aug 2024
- Modality
- Prodrugs/Conditional Activator Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of navoximod and nlg802 in solid tumor (advanced stage). Primary endpoint: Recommended Phase 2 Dose at 90 days. Planned start Oct 2022; status: withdrawn.
02
Drugs
navoximodnlg802
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05469490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05469490.